Welcome to our dedicated page for Beta Bionics SEC filings (Ticker: BBNX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Beta Bionics, Inc. (Nasdaq: BBNX) provides access to the company’s official U.S. Securities and Exchange Commission disclosures. As a commercial-stage medical device company focused on the iLet Bionic Pancreas for insulin-requiring people with diabetes, Beta Bionics uses its filings to report financial results, operational metrics, and significant corporate events.
Investors can review current reports on Form 8-K, which the company uses to announce quarterly financial results and other material information. Recent 8-K filings reference press releases detailing net sales, gross margin, operating expenses, net loss, cash and investment balances, and non-GAAP measures such as adjusted EBITDA, along with reconciliations to the most directly comparable GAAP measures.
Filings also describe operational indicators that are central to Beta Bionics’ business, including installed customer base, new patient starts, and the mix of reimbursement between the Durable Medical Equipment channel and the Pharmacy Benefit Plan channel. These disclosures help readers understand how the iLet Bionic Pancreas is being adopted and reimbursed in practice.
In addition, the company has filed 8-Ks to furnish investor and analyst presentations and to summarize “real-world” iLet data. These materials discuss changes from baseline HbA1c to glucose management indicator, hypoglycemia metrics, and outcomes for users transitioning from multiple daily injections or competitive hybrid-closed loop systems, as well as analyses of usage patterns such as “fully-closed loop” operation.
Through its registration of common stock on the Nasdaq Global Market under the symbol BBNX, Beta Bionics is subject to ongoing reporting obligations. On this page, AI-powered tools can assist by summarizing lengthy filings, highlighting key figures and definitions, and helping readers navigate topics such as non-GAAP metrics, risk factor discussions, and descriptions of clinical and real-world data included in exhibits.
For anyone researching BBNX, the SEC filings page is a primary source for understanding the company’s reported financial condition, regulatory communications, and the detailed context behind its press releases and investor materials.
Beta Bionics Inc ownership disclosure: The Vanguard Group reports beneficial ownership of 0 shares of Common Stock, representing 0% of the class as of 03/13/2026.
The filing is an amendment (Schedule 13G/A) reflecting an internal realignment at The Vanguard Group and states certain subsidiaries will report separately in reliance on SEC Release No. 34-39538. The form is signed by Ashley Grim on 03/26/2026.
Beta Bionics Chief Commercial Officer Mark Hopman sold 2,917 shares of Common Stock in open-market transactions, primarily to cover tax withholding tied to vested restricted stock units. The sales occurred at weighted average prices around $30–31 per share under a pre-arranged Rule 10b5-1 trading plan.
Following these transactions, Hopman directly holds 136,216 shares of Beta Bionics Common Stock, indicating he retains a substantial equity stake in the company.
Beta Bionics, Inc. Chief Medical Officer Russell Steven Jon reported an open-market sale of 1,025 shares of Common Stock at an average price of $29.3359 per share on December 2, 2025. According to the footnote, the shares were sold to cover tax withholding obligations tied to vesting restricted stock units, and he now holds 178,071 shares directly.
Beta Bionics, Inc. reported that Chief Product Officer Mike Mensinger received a grant of employee stock options covering 91,520 shares of common stock. The options have an exercise price of $12.63 per share and expire on February 26, 2036. According to the disclosure, these options vest in 36 equal monthly installments starting on March 1, 2026, meaning the award vests gradually over three years as continued service is provided.
Beta Bionics, Inc. reported that its Chief Medical Officer, Russell Steven Jon, received a grant of stock options. The award covers 91,520 options to purchase common stock at an exercise price of $12.63 per share, expiring on February 26, 2036.
The options were granted at no cost and represent a compensation-related award rather than an open-market purchase. According to the vesting terms, the options will vest in 36 equal monthly installments starting on March 1, 2026, meaning the officer earns the right to exercise them gradually over three years.
Beta Bionics, Inc. reported that President & CEO Sean Saint received a grant of employee stock options on Common Stock. The award covers 287,944 options with an exercise price of $12.63 per share and an expiration date of February 26, 2036.
The options were granted at no cost and are classified as a compensation-related acquisition rather than an open-market purchase. According to the vesting terms, the underlying shares will vest in 36 equal monthly installments starting on March 1, 2026, aligning the CEO’s incentives with longer-term company performance.
Beta Bionics, Inc. reported that Chief Commercial Officer Mark Hopman received an employee stock option grant covering 91,520 shares of common stock. The option has an exercise price of $12.63 per share and expires on February 26, 2036.
The award was granted at no cost on the grant date and vests in 36 equal monthly installments starting on March 1, 2026, reflecting a long-term equity compensation arrangement rather than an open-market share purchase or sale.
Beta Bionics, Inc. reported that Chief Financial Officer Stephen Feider received a grant of employee stock options covering 110,342 shares of common stock. The options have an exercise price of $12.63 per share and expire on February 26, 2036.
The grant was awarded as compensation and did not involve any open-market buying or selling. According to the terms, the options vest in 36 equal monthly installments starting on March 1, 2026, meaning the CFO earns the right to exercise them gradually over three years.
Beta Bionics, Inc. Chief Commercial Officer Mark Hopman sold 353 shares of common stock in an open-market transaction on March 4, 2026. The shares were sold at an average price of $11.57 per share under a pre-arranged Rule 10b5-1 trading plan adopted on May 13, 2025.
After this sale, Hopman directly owned 139,133 shares of Beta Bionics common stock. The filing characterizes the transaction as an open-market sale, and the trading plan structure indicates it was executed under a pre-established schedule rather than at the insider’s discretion on the trade date.
BBNX submitted a Rule 144 notice listing a proposed sale of 353 common shares issued as an equity award, with a transaction date shown as 03/01/2026 and cash as the consideration. The filing also reports prior sales of 2,061 common shares by Mark Hopman on 12/04/2025 for $63,192.28.